Press release
Investigation announced for Investors who lost money with shares of BioAtla, Inc. (NASDAQ: BCAB)
An investigation for investors in BioAtla, Inc. (NASDAQ: BCAB) shares over potential securities laws violations by BioAtla, Inc.
Investors who purchased shares of BioAtla, Inc. (NASDAQ: BCAB), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of BioAtla, Inc. (NASDAQ: BCAB) concerning whether a series of statements by BioAtla, Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
San Diego, CA based BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. BioAtla, Inc. reported that its Net Loss increased from $95.4 million in 2021 to $106.48 million in 2022.
Shares of BioAtla, Inc. (NASDAQ: BCAB) declined from $4.31 per share in February 2023 to as low as $1.42 per share in October 2023.
On February 6, 2024, NASDAQ: BCAB shares closed at $2.70 per share.
Those who purchased shares of BioAtla, Inc. (NASDAQ: BCAB) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors who lost money with shares of BioAtla, Inc. (NASDAQ: BCAB) here
News-ID: 3374737 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for BioAtla
Leading companies in this space include Aadi Bioscience, Acrotech Biopharma, ADC …
Among the 7MM countries, the total Chondrosarcoma Market Size in the United States was ~USD 8.5 million in 2023 and is aniticipated to grow with a significant CAGR during the forecast period (2024-2034).
Emerging therapies like INBRX-109, TIBSOVO (ivosidenib), and others are anticipated to drive growth in the Chondrosarcoma market over the coming years.
DelveInsight's newly released report, "Chondrosarcoma - Market Insights, Epidemiology, and Market Forecast 2034", provides a comprehensive overview of…
Synovial Sarcoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, …
DelveInsight's, "Synovial Sarcoma- Pipeline Insight, 2025" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Synovial Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
According to DelveInsight, the Synovial Sarcoma pipeline includes over 15 major…
Chondrosarcoma Market: Epidemiology, Therapies, Companies, DelveInsight | Aadi B …
Chondrosarcoma Companies are Aadi Bioscience Inc, Acrotech Biopharma LLC, ADC Therapeutics SA, Advenchen Laboratories LLC, Alkermes Plc, Astex Pharmaceuticals Inc, Atlanthera, Bayer AG, BioAtla Inc, BioMed, Valley Discoveries Inc, Bristol-Myers Squibb Co, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Eli Lilly and Co, ENB Therapeutics LLC, Epizyme Inc, Horizon Therapeutics Plc, Incyte Corp, Inhibrx Inc, Iovance Biotherapeutics Inc, Jiangsu Hengrui Medicine Co Ltd, Karyopharm Therapeutics Inc, Les Laboratoires Servier SAS,…
Osteosarcoma Market Set for Groundbreaking Expansion by 2032, Forecasts DelveIns …
The Osteosarcoma market is steadily advancing, driven by evolving treatment strategies and ongoing research. DelveInsight's latest 7MM report offers in-depth insights into key epidemiology trends and market dynamics.
DelveInsight's "Osteosarcoma - Market Insight, Epidemiology, And Market Forecast - 2032 [https://www.delveinsight.com/report-store/osteosarcoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr] report offers an in-depth understanding of the Osteosarcoma, historical and forecasted epidemiology as well as the Osteosarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United…
Investigation for Investors in BioAtla, Inc. (NASDAQ: BCAB) over potential Wrong …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at BioAtla, Inc.
Investors who purchased shares of BioAtla, Inc. (NASDAQ: BCAB) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain BioAtla, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
San Diego, CA based…
Synovial Sarcoma Pipeline Analysis (2023) Covering Clinical Trials, Emerging The …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 14+ key pharma and biotech companies are working on 14+ pipeline drugs in the Synovial Sarcoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Synovial Sarcoma Pipeline Insight, 2023" report…
